143 related articles for article (PubMed ID: 10837819)
1. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine.
Richtand NM; Logue AD; Welge JA; Perdiue J; Tubbs LJ; Spitzer RH; Sethuraman G; Geracioti TD
Brain Res; 2000 Jun; 867(1-2):239-42. PubMed ID: 10837819
[TBL] [Abstract][Full Text] [Related]
2. Dopamine D3 modulation of locomotor activity and sleep in the nucleus accumbens and in lobules 9 and 10 of the cerebellum in the rat.
Barik S; de Beaurepaire R
Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):718-26. PubMed ID: 15913875
[TBL] [Abstract][Full Text] [Related]
3. Nafadotride administration increases D1 and D1/D2 dopamine receptor mediated behaviors.
Dall'Olio R; Gaggi R; Voltattorni M; Tanda O; Gandolfi O
Behav Pharmacol; 2002 Dec; 13(8):633-8. PubMed ID: 12478213
[TBL] [Abstract][Full Text] [Related]
4. Altered behavioral response to dopamine D3 receptor agonists 7-OH-DPAT and PD 128907 following repetitive amphetamine administration.
Richtand NM; Welge JA; Levant B; Logue AD; Hayes S; Pritchard LM; Geracioti TD; Coolen LM; Berger SP
Neuropsychopharmacology; 2003 Aug; 28(8):1422-32. PubMed ID: 12700693
[TBL] [Abstract][Full Text] [Related]
5. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents.
Sautel F; Griffon N; Sokoloff P; Schwartz JC; Launay C; Simon P; Costentin J; Schoenfelder A; Garrido F; Mann A
J Pharmacol Exp Ther; 1995 Dec; 275(3):1239-46. PubMed ID: 8531087
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a functional role of the dopamine D3 receptors in the cerebellum.
Barik S; de Beaurepaire R
Brain Res; 1996 Oct; 737(1-2):347-50. PubMed ID: 8930390
[TBL] [Abstract][Full Text] [Related]
7. Heterogeneity of behavioural profile between three new putative selective D3 dopamine receptor antagonists using an ethologically based approach.
Clifford JJ; Waddington JL
Psychopharmacology (Berl); 1998 Apr; 136(3):284-90. PubMed ID: 9566814
[TBL] [Abstract][Full Text] [Related]
8. Repeated imipramine treatment enhances the 7-OH-DPAT-induced hyperactivity in rats: the role of dopamine D2 and D3 receptors.
Rogóz Z; Skuza G
Pol J Pharmacol; 2001; 53(6):571-6. PubMed ID: 11985330
[TBL] [Abstract][Full Text] [Related]
9. The anticataleptic effect of 7-OH-DPAT: are dopamine D3 receptors involved?
Maj J; Rogóz Z; Skuza G
J Neural Transm (Vienna); 1999; 106(11-12):1063-73. PubMed ID: 10651103
[TBL] [Abstract][Full Text] [Related]
10. Sex differences in nicotine sensitization and conditioned hyperactivity in adolescent rats neonatally treated with quinpirole: role of D2 and D3 receptor subtypes.
Sheppard B; Lehmann J; Cope ZA; Brown RW
Behav Neurosci; 2009 Dec; 123(6):1296-308. PubMed ID: 20001113
[TBL] [Abstract][Full Text] [Related]
11. The dopamine D3 receptor antagonist PNU-99194A fails to block (+)-7-OH-DPAT substitution for D-amphetamine or cocaine.
Baker LE; Svensson KA; Garner KJ; Goodwin AK
Eur J Pharmacol; 1998 Oct; 358(2):101-9. PubMed ID: 9808258
[TBL] [Abstract][Full Text] [Related]
12. Dopamine D2/D3 receptor agonist quinpirole impairs spatial reversal learning in rats: investigation of D3 receptor involvement in persistent behavior.
Boulougouris V; Castañé A; Robbins TW
Psychopharmacology (Berl); 2009 Mar; 202(4):611-20. PubMed ID: 18836703
[TBL] [Abstract][Full Text] [Related]
13. In vivo occupancy of D2 dopamine receptors by nafadotride.
Levant B; Vansell NR
Neuropsychopharmacology; 1997 Aug; 17(2):67-71. PubMed ID: 9252981
[TBL] [Abstract][Full Text] [Related]
14. Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011.
Gyertyán I; Sághy K
Behav Pharmacol; 2004 Jul; 15(4):253-62. PubMed ID: 15252275
[TBL] [Abstract][Full Text] [Related]
15. Enhanced amphetamine sensitivity and increased expression of dopamine D2 receptors in postpubertal rats after neonatal excitotoxic lesions of the medial prefrontal cortex.
Flores G; Wood GK; Liang JJ; Quirion R; Srivastava LK
J Neurosci; 1996 Nov; 16(22):7366-75. PubMed ID: 8929443
[TBL] [Abstract][Full Text] [Related]
16. Locomotor hypoactivity and motor disturbances--behavioral effects induced by intracerebellar microinjections of dopaminergic DA-D2/D3 receptor agonists.
Kolasiewicz W; Maj J
Pol J Pharmacol; 2001; 53(5):509-15. PubMed ID: 11990070
[TBL] [Abstract][Full Text] [Related]
17. D3 dopamine receptor, behavioral sensitization, and psychosis.
Richtand NM; Woods SC; Berger SP; Strakowski SM
Neurosci Biobehav Rev; 2001 Jul; 25(5):427-43. PubMed ID: 11566480
[TBL] [Abstract][Full Text] [Related]
18. Dopamine D3 receptor ligands show place conditioning effect but do not influence cocaine-induced place preference.
Gyertyán I; Gál K
Neuroreport; 2003 Jan; 14(1):93-8. PubMed ID: 12544838
[TBL] [Abstract][Full Text] [Related]
19. Alterations in local cerebral glucose utilization produced by D3 dopamine receptor-selective doses of 7-OH-DPAT and nafadotride.
Levant B; Cross RS; Pazdernik TL
Brain Res; 1998 Nov; 812(1-2):193-9. PubMed ID: 9813322
[TBL] [Abstract][Full Text] [Related]
20. D(3) dopamine receptors are down-regulated in amphetamine sensitized rats and their putative antagonists modulate the locomotor sensitization to amphetamine.
Chiang YC; Chen PC; Chen JC
Brain Res; 2003 May; 972(1-2):159-67. PubMed ID: 12711089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
